Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere JF, Renal Insufficiency Anticancer Medications Study G (2009) Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187(1):69–74. https://doi.org/10.1007/s00408-008-9123-5

Article  PubMed  Google Scholar 

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, VanSchil PE, Hellmann MD, Peters S, Committee EG (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv192–iv237. https://doi.org/10.1093/annonc/mdy275

Article  CAS  PubMed  Google Scholar 

Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756. https://doi.org/10.1200/JCO.1989.7.11.1748

Article  CAS  PubMed  Google Scholar 

Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57(4):401–411. https://doi.org/10.1007/s00280-005-0036-1

Article  PubMed  Google Scholar 

de Rouw N, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ, van den Heuvel MM, Burger DM, Ter Heine R (2021) Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis. Clin Pharmacokinet. https://doi.org/10.1007/s40262-020-00972-1

Article  PubMed  PubMed Central  Google Scholar 

Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AM, van den Heuvel MM, Hendriks LEL, Biesma B, Aerts JGJV, Croes S, Mathijssen R, Huitema ADR, ter Heine R (2021) Toxicity of pemetrexed during renal impairment explained—implications for safe treatment. Int J Cancer 149(8):1576–1584

Article  CAS  PubMed  Google Scholar 

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002

Article  CAS  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

Article  PubMed  PubMed Central  Google Scholar 

Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E (2012) Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367(1):20–29. https://doi.org/10.1056/NEJMoa1114248

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10(2):90–99. https://doi.org/10.1038/nrclinonc.2012.209

Article  CAS  PubMed  Google Scholar 

Bodnar L, Wcislo GB, Smoter M, Gasowska-Bodnar A, Stec R, Synowiec A, Szczylik C (2010) Cystatin C as a parameter of glomerular filtration rate in patients with ovarian cancer. Kidney Blood Press Res 33(5):360–367. https://doi.org/10.1159/000319097

Article  CAS  PubMed  Google Scholar 

Jones M, Denieffe S, Griffin C, Tinago W, Fitzgibbon MC (2017) Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. Pract Lab Med 8:95–104. https://doi.org/10.1016/j.plabm.2017.05.005

Article  PubMed  PubMed Central  Google Scholar 

Kwon WS, Kim TS, Nahm CH, Moon Y, Kim JJ (2018) Aberrant cystatin-C expression in blood from patients with breast cancer is a suitable marker for monitoring tumor burden. Oncol Lett 16(5):5583–5590. https://doi.org/10.3892/ol.2018.9380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Štabuc B, Vrhovec L, Štabuc-Šilih M, Cizej TE (2000) Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem 46(2):193–197. https://doi.org/10.1093/clinchem/46.2.193

Article  PubMed  Google Scholar 

Hoppe A, Seronie-Vivien S, Thomas F, Delord JP, Malard L, Canal P, Chatelut E (2005) Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 11(8):3038–3044. https://doi.org/10.1158/1078-0432.CCR-04-2086

Article  CAS  PubMed  Google Scholar 

Thomas F, Séronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R, Chatelut E (2005) Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 44(12):1305–1316. https://doi.org/10.2165/00003088-200544120-00009

Article  CAS  PubMed  Google Scholar 

Khorashadi M, Beunders R, Pickkers P, Legrand M (2020) Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury. Nephron 144(12):655–661. https://doi.org/10.1159/000509352

Article  CAS  PubMed  Google Scholar 

Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C (2024) The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life. JCO Oncol Pract OP 23:00539

Google Scholar 

de Rouw N, Visser S, Koolen SL, Aerts JG, van den Heuvel MM, Derijks HJ, Burger DM, Ter Heine R (2020) A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer Chemother Pharmacol 85:231–235

Article  PubMed  Google Scholar 

IMPROVE-I. https://clinicaltrials.gov/ct2/show/NCT03656549?term=pemetrexed&recrs=a&phase=1&rank=5.

IMPROVE-II. https://clinicaltrials.gov/ct2/show/NCT03655821?term=pemetrexed&recrs=a&age=1&rank=15.

Cederholm T, Jensen GL, Correia M, Gonzalez MC, Fukushima R, Higashiguchi T, Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs-Tarlovsky V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J, Van Gossum A, Compher C (2019) GLIM criteria for the diagnosis of malnutrition—a consensus report from the global clinical nutrition community. Clin Nutr 38(1):1–9. https://doi.org/10.1016/j.clnu.2018.08.002

Article  CAS  PubMed  Google Scholar 

Donato LJ, Meeusen JW, Lieske JC, Bergmann D, Sparwaßer A, Jaffe AS (2018) Analytical performance of an immunoassay to measure proenkephalin. Clin Biochem 58:72–77. https://doi.org/10.1016/j.clinbiochem.2018.05.010

Article  CAS  PubMed  Google Scholar 

Beunders R, Donato LJ, van Groenendael R, Arlt B, Carvalho-Wodarz C, Schulte J, Coolen AC, Lieske JC, Meeusen JW, Jaffe AS, Pickkers P (2023) Assessing GFR with proenkephalin. Kidney Int Rep 8(11):2345–2355. https://doi.org/10.1016/j.ekir.2023.08.006

Article  PubMed  PubMed Central  Google Scholar 

Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503–512

Article  CAS  PubMed  Google Scholar 

Faber NM (1999) Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibration. Chemomertr Intell Lab Syst 49(1):79–89. https://doi.org/10.1016/S0169-7439(99)00027-1

Article  CAS  Google Scholar 

Marino R, Struck J, Hartmann O, Maisel AS, Rehfeldt M, Magrini L, Melander O, Bergmann A, Di Somma S (2015) Diagnostic and short-term prognostic utility of plasma pro-enkephalin (pro-ENK) for acute kidney injury in patients admitted with sepsis in the emergency department. J Nephrol 28(6):717–724. https://doi.org/10.1007/s40620-014-0163-z

Article  CAS  PubMed  Google Scholar 

Kurata T, Iwamoto T, Kawahara Y, Okuda M (2014) Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3. Drug Metab Pharmacokinet 29(2):148–153

Article  CAS  PubMed  Google Scholar 

Hilbrands LB, Artz MA, Wetzels JF, Koene RA (1991) Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 40(6):1171–1176

Article